DXCM - DexCom - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2521311074
Continuous Glucose Monitoring Systems, Diabetes Management Tools
DexCom Inc, a pioneering medical device company, specializes in the design, development, and commercialization of innovative continuous glucose monitoring (CGM) systems. These systems are designed to empower people with diabetes, as well as healthcare providers, to better manage the condition.
The company's product portfolio includes the Dexcom G6 and Dexcom G7, which are integrated CGM systems that provide real-time glucose data to facilitate informed diabetes management decisions. Additionally, DexCom offers Dexcom Share, a remote monitoring system that enables caregivers and healthcare professionals to track patients' glucose levels remotely.
DexCom also provides the Dexcom Real-Time API, which allows authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This enables a more comprehensive and connected approach to diabetes management. Furthermore, the company offers Dexcom ONE, a system designed to replace finger stick blood glucose testing for diabetes treatment decisions.
In addition, DexCom has submitted the Dexcom Stelo for FDA review, which is specifically designed for people with type 2 diabetes. The company is also collaborating with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products, further expanding its offerings.
DexCom's products are marketed directly to endocrinologists, physicians, and diabetes educators, ensuring that healthcare professionals have access to the latest technology and innovations in diabetes management. With a strong commitment to innovation and improving patient outcomes, DexCom has established itself as a leader in the diabetes management space since its incorporation in 1999.
Headquartered in San Diego, California, DexCom continues to drive progress in the field of diabetes management, providing life-changing solutions for people with diabetes and healthcare providers alike. For more information, visit their website at https://www.dexcom.com.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for DXCM - DexCom - Stock Price & Dividends](https://www.valueray.com/images/drawdown_chart/DXCM.NASDAQ_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for DXCM - DexCom - Stock Price & Dividends](https://www.valueray.com/images/chart/DXCM.NASDAQ_seasonality.png)
DXCM Stock Overview
Market Cap in USD | 42,890m |
Sector | Healthcare |
Industry | Medical Devices |
GiC SubIndustry | Health Care Equipment |
TER | 0.00% |
IPO / Inception | 2005-04-14 |
DXCM Stock Ratings
Growth 5y | 38.0 |
Fundamental | 77.3 |
Dividend | 0.00 |
Rel. Performance vs Sector | -4.09 |
Analysts | 4.44/5 |
Fair Price Momentum | 70.94 USD |
Fair Price DCF | 38.68 USD |
DXCM Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
DXCM Growth Ratios
Growth 12m | -51.65% |
Growth Correlation 12m | 29% |
Growth Correlation 3m | -65% |
CAGR 5y | 10.74% |
CAGR/Mean DD 5y | 0.50 |
Sharpe Ratio 12m | -0.99 |
Alpha vs SP500 12m | -74.72 |
Beta vs SP500 5y weekly | 1.15 |
ValueRay RSI | 0.40 |
Volatility GJR Garch 1y | 38.91% |
Price / SMA 50 | -44.85% |
Price / SMA 200 | -45.83% |
Current Volume | 53914.1k |
Average Volume 20d | 5353.6k |
External Links for DXCM Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of July 27, 2024, the stock is trading at USD 64.00 with a total of 53,914,127 shares traded.
Over the past week, the price has changed by -42.68%, over one month by -43.62%, over three months by -48.53% and over the past year by -48.62%.
According to ValueRays Forecast Model, DXCM DexCom will be worth about 78.9 in July 2025. The stock is currently trading at 64.00. This means that the stock has a potential upside of +23.33%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 151.2 | 136 |
Analysts Target Price | 137 | 114 |
ValueRay Target Price | 78.9 | 23.3 |